Pulmatrix Inc Cash Flow Conversion Efficiency
Pulmatrix Inc cash flow conversion efficiency. Based on the latest financial reports, Pulmatrix Inc (PULM) has a cash flow conversion efficiency ratio of -0.297x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($3.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pulmatrix Inc (2012–2025)
Cash flow conversion efficiency of Pulmatrix Inc from 2012 to 2025. This chart illustrates how Pulmatrix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PULM stock price and chart for real-time trading data and today's change.
Pulmatrix Inc Cash Flow Conversion Ratio Explained
Pulmatrix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pulmatrix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmatrix Inc ranked by their cash flow conversion efficiency. Also see market cap of Pulmatrix Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
-0.167x |
|
Mantle Minerals Ltd
AU:MTL
|
-0.118x |
|
Mint Corp
V:MIT
|
0.055x |
|
Lion Energy Ltd
AU:LIO
|
-0.111x |
|
ONCODES.PREC.MED. EO-34
F:ZR8
|
N/A |
|
Newbury Pharmaceuticals AB
ST:NEWBRY
|
0.072x |
|
Modern Times Group Mtg AB
ST:MTG-A
|
0.079x |
|
Hybrid Financial Services Limited
NSE:HYBRIDFIN
|
0.025x |
Annual Cash Flow Conversion Efficiency for Pulmatrix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Pulmatrix Inc from 2012 to 2025. Review PULM FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.81 Million | $-5.43 Million | -1.426x | -19.06% |
| 2024-12-31 | $8.95 Million | $-10.72 Million | -1.198x | -34.83% |
| 2023-12-31 | $18.00 Million | $-15.98 Million | -0.888x | -42.77% |
| 2022-12-31 | $31.11 Million | $-19.36 Million | -0.622x | -49.66% |
| 2021-12-31 | $47.45 Million | $-19.73 Million | -0.416x | +22.93% |
| 2020-12-31 | $23.14 Million | $-12.48 Million | -0.539x | -284.04% |
| 2019-12-31 | $11.02 Million | $3.23 Million | 0.293x | +120.71% |
| 2018-12-31 | $11.84 Million | $-16.76 Million | -1.415x | +0.91% |
| 2017-12-31 | $10.14 Million | $-14.48 Million | -1.428x | +5.52% |
| 2016-12-31 | $8.76 Million | $-13.24 Million | -1.512x | -295.18% |
| 2015-12-31 | $32.61 Million | $-12.47 Million | -0.383x | -88.47% |
| 2014-12-31 | $14.63 Million | $-2.97 Million | -0.203x | 0.00% |
| 2013-12-31 | $14.63 Million | $-2.97 Million | -0.203x | +97.76% |
| 2012-12-31 | $47.00K | $-426.00K | -9.064x | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more